Targeted protein kinase c inhibitors and uses thereof

Details Targeted protein kinase c inhibitors and uses thereof Targeted protein kinase c inhibitors and uses thereof

A - Human Necessities

61

K

A61K 47/48 (2006.01) A61K 31/7076 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) A61K 38/16 (2006.01) A61P 3/10 (2006.01) A61P 9/00 (2006.01) A61P 35/00 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 14/00 (2006.01) C12N 9/12 (2006.01)

Patent

CA 2659961

Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TlMs) of the present invention are capable of inhibiting one or more PKC isoforms. The TIMs can be designed to target a specific PKC isoform by selection of a PRE component that is shown to preferentially target that PKC isoform. The TIMs are useful as therapeutic agents in the treatment of PKC-related diseases and disorders, such as cancer, psoriasis, angiogenesis, restenosis, atherosclerosis, cardiovascular disease, hypertension, diabetes, neurological disorders, rheumatoid arthritis, kidney disorders, inflammatory disorders and autoimmune disorders.

La présente invention concerne des isoformes de protéine kinase C mammifères qui comprennent une fraction d~inhibiteur, permettant d~inhiber l'activité de la protéine kinase, associée de manière fonctionnelle à un élément de reconnaissance de peptide (ERP) présentant une affinité avec un ou plusieurs isoformes de PKC. Les molécules inhibitrices ciblées (MIT) de la présente invention peuvent inhiber un ou plusieurs isoformes de PKC. Les MIT peuvent être conçues pour cibler un isoforme de PKC spécifique par la sélection d~un composant ERP qui a été observé comme ciblant de préférence cet isoforme de PKC. Les MIT sont utiles en tant qu~agents thérapeutiques dans le cadre du traitement de maladies et de troubles associés au PKC, tels que le cancer, le psoriasis, l~angiogenèse, la resténose, l~athérosclérose, les maladies cardiovasculaires, l~hypertension, le diabète, les troubles neurologiques, la polyarthrite rhumatoïde, les rénopathies, les troubles inflammatoires et les affections auto-immunes.

Affiliated with

Also associated with

Rating

Targeted protein kinase c inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted protein kinase c inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted protein kinase c inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1826412